Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 10;13(8):2185.
doi: 10.3390/jcm13082185.

Topical Treatments in Atopic Dermatitis: An Expansive Review

Michelle Lazar  1 , Aurore D Zhang  1 , Neelam A Vashi  1
Affiliations
Review

Topical Treatments in Atopic Dermatitis: An Expansive Review

Michelle Lazar et al. J Clin Med. .

Abstract

Atopic dermatitis (AD) is a common inflammatory skin condition found worldwide. It impacts patient quality of life (QoL) and is thought to arise as an inflammatory response to epidermal barrier dysfunction and hypersensitivity. AD can lead to large out-of-pocket costs and increased healthcare expenses over a lifetime. An analysis of all randomized control trials conducted since 1990 on topical therapies for AD were reviewed, including 207 trials in the final analysis. It was found that an average of 226 patients were enrolled over 2.43 arms. Common topical treatments included corticosteroids, calcineurin inhibitors, JAK inhibitors, and phosphodiesterase inhibitors. The most utilized tools to identify treatment efficacy were the EASI, IGA, SCORAD, and PGA. There was a paucity of data on trials that evaluated efficacy, QoL, and cost of treatment simultaneously. This review highlights the need for comprehensive trials that evaluate multiple aspects of treatment, including financial cost and QoL impact, to ensure each patient has the best treatment modality for the management of their AD.

Keywords: atopic dermatitis; cost of treatment; inflammatory skin conditions; over-the-counter treatments; quality of life; steroids; topical therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA-based flow diagram depicting inclusion and exclusion criteria. In total, 207 unique studies were included in this analysis.
Figure 2
Figure 2
Graphical representation of commonly used metrics for measurement of disease severity and treatment progression in AD.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Raimondo A., Lembo S. Atopic Dermatitis: Epidemiology and Clinical Phenotypes. Dermatol. Pract. Concept. 2021;11:e2021146. doi: 10.5826/dpc.1104a146. - DOI - PMC - PubMed
    1. Smith Begolka W., Chovatiya R., Thibau I.J., Silverberg J.I. Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States. Dermatitis. 2021;32:S62–S70. doi: 10.1097/DER.0000000000000715. - DOI - PMC - PubMed
    1. David Boothe W., Tarbox J.A., Tarbox M.B. Atopic Dermatitis: Pathophysiology. Manag. Atopic Dermat. Methods Chall. 2017;1027:21–37. doi: 10.1007/978-3-319-64804-0_3. - DOI - PubMed
    1. Loset M., Brown S.J., Saunes M., Hveem K. Genetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance. Dermatology. 2019;235:355–364. doi: 10.1159/000500402. - DOI - PubMed
    1. Galli E., Gianni S., Auricchio G., Brunetti E., Mancino G., Rossi P. Atopic dermatitis and asthma. Allergy Asthma Proc. 2007;28:540–543. doi: 10.2500/aap2007.28.3048. - DOI - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources